These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37657236)

  • 21. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
    Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
    Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40.
    Hamano R; Huang J; Yoshimura T; Oppenheim JJ; Chen X
    Eur J Immunol; 2011 Jul; 41(7):2010-20. PubMed ID: 21491419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.
    Verwoerd A; Hijdra D; Vorselaars AD; Crommelin HA; van Moorsel CH; Grutters JC; Claessen AM
    Clin Exp Immunol; 2016 Aug; 185(2):263-70. PubMed ID: 27158798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical Application of Tetrandrine Nanoemulsion Promotes the Expansion of CD4
    Chen S; Lin Z; He T; Islam MS; Xi L; Liao P; Yang Y; Zheng Y; Chen X
    Front Immunol; 2022; 13():800283. PubMed ID: 35464441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
    Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
    Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory T cell induction by mesenchymal stem cells depends on the expression of TNFR2 by T cells.
    Naserian S; Shamdani S; Arouche N; Uzan G
    Stem Cell Res Ther; 2020 Dec; 11(1):534. PubMed ID: 33303019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients.
    Yip WK; Abdullah MA; Yusoff SM; Seow HF
    Clin Exp Immunol; 2009 Mar; 155(3):412-22. PubMed ID: 19220831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
    Govindaraj C; Tan P; Walker P; Wei A; Spencer A; Plebanski M
    Clin Cancer Res; 2014 Feb; 20(3):724-35. PubMed ID: 24297862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced frequency and functional defects of CD4
    Luo L; Zeng X; Huang Z; Luo S; Qin L; Li S
    Reprod Biol Endocrinol; 2020 Jun; 18(1):62. PubMed ID: 32522204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
    Liao P; Jiang M; Islam MS; Wang Y; Chen X
    Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells.
    Kakita N; Kanto T; Itose I; Kuroda S; Inoue M; Matsubara T; Higashitani K; Miyazaki M; Sakakibara M; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    Int J Cancer; 2012 Dec; 131(11):2573-83. PubMed ID: 22419479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bivalent structure of a TNFR2-selective and agonistic TNF-α mutein Fc-fusion protein enhances the expansion activity of regulatory T cells.
    Inoue M; Tsuji Y; Ueno R; Miyamoto D; Tanaka K; Moriyasu Y; Shibata S; Okuda M; Ando D; Abe Y; Kamada H; Tsunoda SI
    Sci Rep; 2023 Aug; 13(1):13762. PubMed ID: 37612373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice.
    Pan XD; Mao YQ; Zhu LJ; Li J; Xie Y; Wang L; Zhang GB
    Chin Med J (Engl); 2012 Jun; 125(11):2004-11. PubMed ID: 22884069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and function of TNF and IL-1 receptors on human regulatory T cells.
    Mercer F; Kozhaya L; Unutmaz D
    PLoS One; 2010 Jan; 5(1):e8639. PubMed ID: 20066156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paeoniflorin ameliorates murine lupus nephritis by increasing CD4
    Liang CL; Lu W; Qiu F; Li D; Liu H; Zheng F; Zhang Q; Chen Y; Lu C; Li B; Dai Z
    Biochem Pharmacol; 2021 Mar; 185():114434. PubMed ID: 33513343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD45RA-Foxp3high but not CD45RA+Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression.
    Sun W; Li WJ; Wu CY; Zhong H; Wen WP
    J Exp Clin Cancer Res; 2014 Apr; 33(1):35. PubMed ID: 24761979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progranulin promotes tumour necrosis factor-induced proliferation of suppressive mouse CD4⁺ Foxp3⁺ regulatory T cells.
    Hu Y; Xiao H; Shi T; Oppenheim JJ; Chen X
    Immunology; 2014 Jun; 142(2):193-201. PubMed ID: 24383743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The decreased proportion of CD4
    Yang D; Wu M
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Sep; 38(9):831-836. PubMed ID: 36082714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spatial architecture of regulatory T-cells correlates with disease progression in patients with nasopharyngeal cancer.
    Zhou F; Shayan G; Sun S; Huang X; Chen X; Wang K; Qu Y; Wu R; Zhang Y; Liu Q; Zhang J; Luo J; Shi X; Liu Y; Liang B; Li YX; Wang J; Yi J
    Front Immunol; 2022; 13():1015283. PubMed ID: 36439177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4+CD25+CD127-Foxp3+ and CD8+CD28- Tregs in Renal Transplant Recipients: Phenotypic Patterns, Association With Immunosuppressive Drugs, and Interaction With Effector CD8+ T Cells and CD19+IL-10+ Bregs.
    Aly MG; Ibrahim EH; Karakizlis H; Weimer R; Opelz G; Morath C; Zeier M; Ekpoom N; Daniel V
    Front Immunol; 2021; 12():716559. PubMed ID: 34335631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.